This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

“We look forward to sharing these data among our peers in the oncology research community at this year’s AACR meeting as we prepare to initiate clinical development with AV-203, our internally-discovered ErbB3 inhibitory antibody, in the first half of this year,” said Jeno Gyuris, Ph.D., senior vice president and chief scientific officer at AVEO. “ErbB3 is widely expressed in many human cancers and its over-expression is often associated with poor prognosis in patients. An increasing body of evidence implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 has demonstrated high affinity binding to ErbB3 and the ability to potently inhibit both ligand-dependent and ligand-independent ErbB3 signaling in vitro and in vivo.”

The schedule for AVEO’s poster presentations is as follows:

Date & Time:

          Sunday, April 1, 2012 from 1:00 to 5:00 p.m. (CDT)

Poster Title:

The effect of food on the pharmacokinetics of tivozanib

Abstract:

#752

Location:

McCormick Place West, Hall F, Poster Section 28, #6
 

Date & Time:

Monday, April 2, 2012 from 1:00 to 5:00 p.m. (CDT)

Poster Title:

 

AV-203, a humanized ErbB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ErbB3 signaling in vitro and in vivo

Abstract:

#2509

Location:

McCormick Place West, Hall F, Poster Section 19, #4
 

Date & Time:

Tuesday, April 3, 2012 from 8:00 a.m. to 12:00 p.m. (CDT)

Poster Title:

Pharmacokinetics and pharmacodynamics of AV-203, a humanized anti-ErbB3 antibody

Abstract:

#3787

Location:

McCormick Place West, Hall F, Poster Section 30, #22

Following the meeting, the AVEO posters will be available in the publications section of the AVEO website at investor.aveopharma.com.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,979.13 +59.54 0.35%
S&P 500 1,986.51 +4.91 0.25%
NASDAQ 4,526.4820 -1.0320 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs